Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-01-22
2010-12-07
Chong, Kimberly (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C536S024310, C536S024300
Reexamination Certificate
active
07846907
ABSTRACT:
The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19-24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
REFERENCES:
patent: 5912332 (1999-06-01), Agrawal et al.
patent: 6423489 (2002-07-01), Anderson et al.
patent: 6486299 (2002-11-01), Shimkets
patent: 6506559 (2003-01-01), Fire et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0114784 (2002-08-01), Li et al.
patent: 2002/0123034 (2002-09-01), Canaani et al.
patent: 2002/0132346 (2002-09-01), Cibelli
patent: 2002/0162126 (2002-10-01), Beach et al.
patent: 2002/0173478 (2002-11-01), Gewirtz
patent: 2003/0027783 (2003-02-01), Zernicka-Goetz et al.
patent: 2003/0108923 (2003-06-01), Tuschl et al.
patent: 2003/0125281 (2003-07-01), Lewis et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0148341 (2003-08-01), Sin et al.
patent: 2003/0157030 (2003-08-01), Davis et al.
patent: 2003/0176671 (2003-09-01), Reed et al.
patent: 2003/0180756 (2003-09-01), Shi et al.
patent: 2003/0190635 (2003-10-01), McSwiggen
patent: 2003/0198627 (2003-10-01), Arts et al.
patent: 2004/0203011 (2004-10-01), Morris et al.
patent: 199 03 713 (1999-01-01), None
patent: 19956568 (1999-11-01), None
patent: 20023125 (2000-01-01), None
patent: 10100588 (2001-01-01), None
patent: 10163098 (2001-12-01), None
patent: 10235620.3 (2002-01-01), None
patent: 10100586 (2002-04-01), None
patent: 10230996 (2002-07-01), None
patent: 10230997 (2002-07-01), None
patent: 1214945 (2000-01-01), None
patent: WO 99/32619 (1999-07-01), None
patent: WO 99/53050 (1999-10-01), None
patent: WO 99/61631 (1999-12-01), None
patent: WO 00/01846 (2000-01-01), None
patent: 00/44895 (2000-08-01), None
patent: WO 00/44914 (2000-08-01), None
patent: WO 00/63364 (2000-10-01), None
patent: WO 00/68374 (2000-11-01), None
patent: WO 01/18197 (2001-03-01), None
patent: WO 01/29058 (2001-04-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/42443 (2001-06-01), None
patent: WO 01/48183 (2001-07-01), None
patent: WO 01/68836 (2001-09-01), None
patent: WO 01/70949 (2001-09-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 02/44321 (2001-11-01), None
patent: WO 01/92513 (2001-12-01), None
patent: WO 02/16620 (2002-02-01), None
patent: WO 02/26780 (2002-04-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 0244321 (2002-06-01), None
patent: WO 02/055692 (2002-07-01), None
patent: WO 02/055693 (2002-07-01), None
patent: WO 02/061034 (2002-08-01), None
patent: WO 02/068635 (2002-09-01), None
patent: WO 02/068637 (2002-09-01), None
patent: WO 03/006477 (2003-01-01), None
patent: WO 03/012052 (2003-02-01), None
patent: WO 03/012082 (2003-02-01), None
patent: WO 03/016572 (2003-02-01), None
patent: WO 03/033700 (2003-04-01), None
patent: WO 03/035082 (2003-05-01), None
patent: WO 03/035083 (2003-05-01), None
patent: WO 03/035868 (2003-05-01), None
patent: WO 03/035869 (2003-05-01), None
patent: WO 03/035870 (2003-05-01), None
patent: WO 03/035876 (2003-05-01), None
patent: WO 03/070283 (2003-08-01), None
patent: WO 03/070750 (2003-08-01), None
patent: WO 03/070969 (2003-08-01), None
patent: WO 03/070972 (2003-08-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO 03/080794 (2003-10-01), None
patent: WO 03/080807 (2003-10-01), None
Caplen NJ. RNAi as a Gene Therapy Approach. Expert Opinon. Biol. Thera. (2003) vol. 3(4) 575-586. Ashley Publications Ltd.
Paroo et al. Challenges for RNAi in vivo. Trends in Biotechnology (2004), vol. 22(8) 390-394. Elsevier.
Adams, A. RNA therapeutics enter clinical trials. Scientist (2005), vol. 19:Issue 1. Institute for Scientific Information.
Hammond et al. Post-transcriptional gene silencing by double-stranded RNA Nature Reviews, 2001, vol. 2, 110-119. MacMillan Magazines Ltd.
Matsushita et al. Ribozymes Cleave the AML1-MTG8 Fusion Transcript and Inhibit Proliferation of Leukemic Cells with t(8;21). Biochemical and Biophysical Research Communications, 1995, vol. 215, No. 2: 431-437.
Novina et al. The RNAi Revolution. Nature 2004, vol. 430: 161-164. Nature Publishing Group.
Holen, T. et al., (2002), “Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor”,Nucleic Acids Research, 30(8):1757-1766.
Ambros, V., (2001), “Dicing Up RNAs”,Science, 293:811-813.
Elbashir, S.M. et al., (2001), “Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells”,Nature, 411:494-498.
Gautschi, O. et al., (2001), “Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins”,Journal of the National Cancer Institute, 93(6):463-471.
Lipardi, C. et al., (2001), “RNAi as Random Degradative PCR: siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs”,Cell, 107:297-307.
Sharp, P.A., (2001), “RNA interference—2001”,Genes&Development, 15:485-490.
Sijen, T. et al., (2001), “On the Role of RNA Amplification in dsRNA-Triggered Gene Silencing”,Cell, 107:465-476.
Bass, B.L., (2000), “Double-Stranded RNA as a Template for Gene Silencing”,Cell, 101:235-238.
Cobaleda, C. et al., (2000), “In vivo inhibition by a site-specific catalytic RNA subunit of Rnase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment”,Blood, 95(3):731-737.
Hammond, S.M. et al., (2000), “An RNA-directed nuclease mediates post-transcriptional gene silencing inDrosophilacells”,Nature, 404:293-296.
Yang, D. et al., (2000), “Evidence that processed small dsRNAs may mediate sequence-specific mRNA degradation during RNAi inDrosophilaembryos”,Current Biology, 10:1191-1200.
Wianny, F. et al., (2000), “Specific interference with gene function by double-stranded RNA in early mouse development”,Nature Cell Biology, 2:70-75.
Zamore, P.D. et al., (2000), “RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals”,Cell, 101:25-33.
Fire, A., (1999), “RNA-triggered gene silencing”,TIG, 15(9):358-363.
Tuschl, T. et al., (1999), “Targeted mRNA degradation by double-stranded RNA in vitro”,Genes&Development, 13:3191-3197.
Wild, K. et al., (1999), “The 2 Å structure of helix 6 of the human signal recognition particle RNA”,Structure, 7(11):1345-1352.
Montgomery, M.K. et al., (1998), “Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression”,TIG, 14(7):255-258.
Lowy, D.R. et al., (1993), “Function and Regulation of RAS”,Annu. Rev. Biochem., 62:851-891.
Downward, J. et al., (1990), “Identification of a nucleotide exchange-promoting activity for p21ras”, Proc. Natl. Acad. Sci. USA, 87:5998-6002.
Gibbs, J.B. et al., (1988), “Purification of ras GTPase activating protein from bovine brain”,Proc. Natl. Acad. Sci. USA, 85:5026-5030.
International Search Report of International Application No. PCT/EP02/00151.
Caplen, N.J., (2002), “A new approach to the inhibition of gene expression”,Trends in Biotechnology, 20(2):49-51.
Caplen, N.J. et al., (2001), “Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems”,Proc. Natl. Acad. Sci. USA, 98(17):9742-9747.
Doench, J.G. et al., (2003), “siRNAs can function as miRNAs”,Genes&Development, 17:438-442.
Donzé, O. et al., (2002), “RNA interference in mammalian cells using siRNAs synthesized with T7 RNA Polymerase”,Nucleic Acids Research, 30(10):e46(4pages).
Elbashir, S.M. et al., (2001), “RNA interference is mediated by 21- and 22-nucleo
Heidenreich Olaf
Kreutzer Roland
Limmer Stefan
Vornlocher Hans-Peter
Alnylam Pharmaceuticals, Inc.
Chong Kimberly
Fenwick & West LLP
LandOfFree
Double-stranded RNA (dsRNA) and method of use for inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Double-stranded RNA (dsRNA) and method of use for inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Double-stranded RNA (dsRNA) and method of use for inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4233231